Ipsen S.A. (EPA:IPN)
France flag France · Delayed Price · Currency is EUR
103.70
-8.10 (-7.25%)
Jul 31, 2025, 5:35 PM CET

Ipsen Company Description

Ipsen S.A. operates as a biopharmaceutical company worldwide.

The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases.

The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Ipsen S.A.
Ipsen logo
CountryFrance
Founded1929
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees5,358
CEODavid Loew

Contact Details

Address:
65, quai Georges Gorse
Boulogne-Billancourt, 92100
France
Phone33 1 58 33 50 00
Websiteipsen.com

Stock Details

Ticker SymbolIPN
ExchangeEuronext Paris
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberFR0010259150
SIC Code2834

Key Executives

NamePosition
David LoewMD, Chief Executive Officer and Director
Aymeric Le ChatelierExecutive Vice President and Chief Financial Officer
Dr. Aidan Murphy Ph.D.Executive Vice President and Head of Technical Operations
Khalid DeojeeSenior Manager of Investor Relations
Francois GarnierExecutive Vice President of Legal Affairs, General Counsel and Chief Business Ethics Officer
Regis MulotExecutive Vice President and Chief Human Resources Officer
Dominique BeryHead of Nordics and Baltics
Bartosz Bednarz D.D.S.Executive Vice President and Head of Global Product and Portfolio Strategy
Philippe Lopes-Fernandes CBOExecutive Vice President and Chief Business Officer
Dr. James Levine M.D., Ph.D.President of Fondation Ipsen